Imatinib mesylate.

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Imatinib mesylate represents a novel class of small-molecule anticancer agents.
• These agents exhibit high selectivity for specific molecular targets driving cancer.
• Imatinib targets protein tyrosine kinases, including BCR-ABL, c-KIT, and PDGF-R.

Purpose of the Study:

• To review the role of imatinib in treating chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST).
• To discuss the efficacy, tolerability, and adverse events associated with imatinib therapy.
• To explore the mechanisms of resistance to imatinib and the development of subsequent-generation inhibitors.

Main Methods:

• Literature review of imatinib's clinical activity and resistance mechanisms.
• Analysis of imatinib's targeted inhibition of specific protein tyrosine kinases.
• Examination of clinical trial data regarding efficacy and adverse events.

Main Results:

• Imatinib demonstrates remarkable clinical activity in CML and GIST patients.
• Treatment is generally well-tolerated with manageable side effects like edema and myelosuppression.
• Mechanisms of resistance include BCR-ABL amplification and mutations, necessitating new therapeutic strategies.

Conclusions:

• Imatinib is a cornerstone therapy for CML and GIST.
• Understanding resistance pathways is crucial for advancing tyrosine kinase inhibitor development.
• Second- and third-generation inhibitors have been developed to overcome imatinib resistance.